Navigation Links
Haemacure Raises $7.8 Million and is Fully Funded Beyond First-Patient-In-Clinic
Date:6/16/2008

HAE:TSX

MONTREAL, June 16 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announces that it has raised $7.8 million through the exercise of amended Series B warrants and broker warrants issued as part of the private placement concluded in January 2007.

"I sincerely thank our shareholders who demonstrated their strong support by exercising their warrants. We now have the financial resources to execute on all of the necessary milestones to get our fibrin sealant into the clinic in Q1-09. This financing significantly reduces the financial risk. All of our time and attention will be focused on execution and getting a green light from the FDA to enter clinical trials." said Joseph Galli, Chairman and CEO of Haemacure.

Manufacturing Facility

On June 4th, Haemacure began fractionating plasma in its new facility in Sarasota, Florida. It is on-schedule and on-budget to produce fibrin sealant clinical lots during Q3-08 and to file an amendment to its existing IND with the U.S. FDA during Q4-08.

Haemacure's fractionation facility is the first and only U.S.-based manufacturing facility for fibrin sealant destined for the U.S. market and this is of significant strategic value.

Fibrin Sealant Pivotal Clinical Trials

The safety of Haemacure's lead product candidate, all-human fibrin sealant, was demonstrated in past clinical trials as no serious adverse events related to the product were reported. The efficacy of the product was also significantly superior to the standard of care used in the control group.

New Preclinical Study in Adhesion Prevention

Encouraged by the positive results of the preclinical study Haemacure conducted on the efficacy of its all-human fibrin sealant in preventing the formation of post-surgical adhesions, Haemacu
'/>"/>

SOURCE HAEMACURE CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
2. Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
3. Haemacure Reports on Financing Progress and Second Quarter Results
4. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
5. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Haemacure financing receives shareholder consent - Series B Warrants are amended
7. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
8. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
9. Haemacure Reports on its annual general and special meeting of shareholders
10. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
11. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB filed ... Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant . ... migration of their Implanon® implants, inability to locate the implants, unsuccessful and invasive ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... The alarm was ringing. Hugh Chatfield, survivor ... out of the window, he recalled that his equipment was set up to depict the ... he jumped out of bed. , The photo speaks for itself. Chatfield is also a ...
(Date:7/31/2015)... ... July 31, 2015 , ... Patients with higher levels of ... study published today in Nature Communications and led by researchers from the Icahn School ... variations in the gene RTN1 led to greater production of the related RNT1 protein, ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... proud to announce that their latest designer handbag line will be named for ... an Internet sensation as the first globally recognized model with Down syndrome, gracing ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe ... a newly redesigned website at Healthpointe.net. The new website will feature a sleek ... The redesign serves to provide smoother interactions between patients and the Healthpointe clinics ...
Breaking Medicine News(10 mins):Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Healthpointe Announces Newly Redesigned Website 2
... Center have found a new technique that employs RNA, a ... lead to therapeutics// for conditions in which nudging a gene ... with a novel research tool to investigate the role that ... paper appearing online at Nature Chemical Biology and in an ...
... right type of fat may actually keep child obesity at ... unsaturated fat and very little omega-3. ,A study ... was undertaken by scientists at Goteborg University. These children belong ... revealed that 23% of the children belong to an overweight ...
... MPs, members of the Committee of Public Accounts, has come out ... ,Levels of obesity in children aged two to 10 years ... 2004, according to the Health Survey for England. , ... as obese. ,The Public Accounts Committee report ...
... Boston ranked the top city in America for having a ... conducted by Fit Pregnancy magazine, Boston’s outstanding// healthcare resources is ... like low birth risks and family recreation. The magazine shared ... Wednesday. ,Mayor Thomas M. Menino, while commenting on ...
... study finds that CT scans used in emergency rooms spotted ... MRI scans which are better in identifying any type of ... to magnetic resonance imaging,” wrote Dr. Geoffrey A. Donnan and ... note accompanying the study report. ,Doctors argue that ...
... project to revamp its healthcare infrastructure and train health ... expected to benefit over 45 million people. ,Health ... medical facilities at the village level and the project ... scheme would benefit over 45 million people at the ...
Cached Medicine News:Health News:A Novel Technique Nudges Genes Into Activity 2Health News:A Novel Technique Nudges Genes Into Activity 3Health News:Under-Elevens Hurtle Towards Obesity, British MPs Call for Action 2Health News:Mega Project to Revamp Karnataka’s Healthcar 2
(Date:7/31/2015)... 2015 Quietly, sedately, Morocco,s pharmaceutical ... domestic pharmaceutical industry is strong, with a well-developed base ... international standards. One place where the quality ... Africa: Morocco has quietly become the second largest African ... . Indeed, Moroccan pharma companies have been making ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/31/2015)... , July 31, 2015 ... solutions for video, data and cloud computing operators ... a leading pharma giant for Internet of Things ... IoT applications offered on subscription model. ... Pharma giant is striving for business innovations to ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... YORK, Oct. 6, 2011 Reportlinker.com ... report is available in its catalogue: ... Market to 2017 - Patent Expiry ... Impact Dyslipidemia Market Value ...
... NEW YORK, Oct. 6, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0254328/The-Future-of-European-Pharmaceutical-Distribution.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical ... to reduce internal costs for manufacturers, and ...
Cached Medicine Technology:Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 2Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 3Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 4Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 5Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 6Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 7Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 8Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 9Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 10Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 11Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 12Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 13Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 14Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 15The Future of European Pharmaceutical Distribution 2The Future of European Pharmaceutical Distribution 3The Future of European Pharmaceutical Distribution 4The Future of European Pharmaceutical Distribution 5The Future of European Pharmaceutical Distribution 6The Future of European Pharmaceutical Distribution 7The Future of European Pharmaceutical Distribution 8The Future of European Pharmaceutical Distribution 9
... A necessary addition to ... the Reichert Trial Frame ... and smooth controls for ... robust design, high-quality materials, ...
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... Illumination is provided by a cool-running, ... light only what you need to see ... best of all they are maintenance free ... light bulb. Every Phoroptor comes with a ...
Medicine Products: